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Ganciclovir, administered via an intravenous central line
over 6 weeks to newborn infants symptomatically infected
with cytomegalovirus (CMV), has been shown to prevent
progressive disease, as gauged by less hearing deteriora-
tion, in a randomized phase III trial [2]. However, almost
two-thirds of treated infants have significant neutropenia
during therapy, and some get infections related to indwell-
ing intravenous catheters [2, 3]. The valine ester of
ganciclovir, valganciclovir, is an orally applicable prodrug
successfully used in transplant recipients and human
immunodeficiency virus (HIV) patients. Bioavailability
of ganciclovir from oral valganciclovir has been reported to
be about 60% in adults and 43% in a 6-year-old child [1]
while it has been difficult to attain stable ganciclovir serum
levels with oral valganciclovir in a newborn infant as was
recently published [4].
We report on a term newborn girl with symptomatic
CMV infection presenting with hepatosplenomegaly,
“blueberry muffin” rash, thrombocytopenia, elevated liver
enzymes, lenticulostriate vasculopathy, periventricular
calcifications, partial polymicrogyria, and severe hearing
impairment (hearing thresholds 100 and 120 dB). She
tested positive for anti-CMV IgG and IgM, and CMV was
detected in urine and blood by culture and polymerase
chain reaction (PCR).
On day 4 of life, ganciclovir was started via central venous
access as described [2]. While the rash and hepatospleno-
megaly resolved completely, there was progressive anemia
(nadir of hemoglobin 7.8 g/dl) treated with oral iron. Platelet
counts dropped to 26,000/μl immediately prior to start of
ganciclovir but recovered quickly thereafter, remaining
above 200,000/μl. However, intravenous ganciclovir was
reduced and eventually discontinued when her absolute
neutrophil counts (ANC) dropped <500/μl (Table 1). The
central line was removed, and after informed parental
consent and notification of the Swiss federal healthcare
authority, oral treatment with valganciclovir (Valcyte,
Roche, Switzerland) was commenced as soon as ANC
rose to 540 cells/μl at 20 days of life. Oral valganciclovir was
incrementally increased up to 56 mg/kg per day as long as
ganciclovir serum trough levels were <1 mg/l and ANC
>1,000/μl. This regimen did not result in relapse of
neutropenia, while CMV viral load fell below the detection
limit of 600 copies/ml (Table 1). Valganciclovir was
discontinued after a total of 6 weeks on medication [2]. No
further side effects were noted. For the last 4 weeks, she was
seen as an outpatient. When last examined at 9 months of
age, she was well, equipped with hearing aids, and being
evaluated for cochlear implants.
Thus, substituting oral valganciclovir for intravenous
ganciclovir in term newborn infants is feasible, resulting in
ganciclovir serum concentrations in the range associated
with CMV control [6], eventual suppression of CMV
viremia, and significant cost savings, as much of the
therapy can be done on an outpatient basis. In addition, it
allows for studies aiming at extending the time of
administration beyond 6 weeks [4] and also including not
overtly symptomatic infants with congenital CMV infec-
tion [5]. However, the complex relationship between
valganciclovir dose and serum levels in this and the only
other report so far [4] points to the need for prior
pharmacokinetic studies.
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Table 1 Absolute neutrophil
counts (ANC), ganciclovir
plasma trough levels (kindly
measured by Dr. M. Oellerich,
Göttingen, Germany) and
CMV plasma loads (kindly de-
termined by Dr. K. Hamprecht,
Tübingen, Germany) in the
newborn infant with symptom-

















4 880 2×12 (9.2)
7 825 2×12 (9.7) 0.26
15 517 2×6 (4.5) 0.64 1,715
18 442 – –
20 540 2×18 (12.8)
24 528 2×18 (12.4) 1.33 671
29 998 2×18 (12.0) 0.41
31 1596 2×38 (24.9)
38 1541 2×80 (49.4)
43 956 2×100 (58.9) 0.97 <600
50 1400 2×100 (56.0) 0.80 <600
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